Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head
July 25 2016 - 11:00AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced that
Fouad Namouni, M.D., has been appointed Oncology Development Head,
effective July 25, 2016. Dr. Namouni will be responsible for
leading the execution of a comprehensive development strategy for
the company’s robust oncology pipeline from the early development
stage through commercialization. He will continue to report to
Francis Cuss, MB Bchir, FRCP, executive vice president, chief
scientific officer, and remain a member of the R&D Leadership
Team. Namouni most recently served as head of Medical, leading the
worldwide medical organization and prior to that, was the
development lead for Yervoy and Opdivo.
“Fouad has demonstrated highly successful strategic and
visionary leadership in oncology and immuno-oncology drug
development and medical affairs throughout his career at
Bristol-Myers Squibb,” said Cuss. “As a trained pediatric
oncologist, Fouad brings to this role exceptional clinical
experience and an unwavering commitment to patients. I am confident
that our oncology development programs will continue to thrive
under his leadership.”
Namouni joined Bristol-Myers Squibb in France in 1999 as
life-cycle manager for Taxol and has held positions of increasing
responsibility in R&D since. Namouni moved to the U.S. in
September 2006 where he became responsible for the development of
Erbitux. Before taking his current role as head of Medical, Namouni
was the development lead for Opdivo and Yervoy. Earlier in his
career, Namouni was a pediatric oncologist at Institut Curie in
Paris where his focus was clinical research for the treatment of
pediatric tumors. He received his medical degree from the
University of Annaba Medical School in Algeria and his Pediatrics
degree from Université Rene Descartes in Paris, France. He also
received his Pediatric Oncology and Hematology degree and M.S. in
Clinical and Experimental Pharmacology from Université Paris-Sud in
France.
Additionally, the company announced today that Michael Giordano
has retired from Bristol-Myers Squibb after more than 17 years of
leadership and service. Since joining the company, Giordano and the
teams he has led have developed and delivered more than a dozen
medicines to patients, marking a successful and distinguished drug
development career.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160725005726/en/
Bristol-Myers SquibbMedia:Sarah Koenig,
609-252-4145sarah.koenig@bms.comorInvestors:Bill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024